Human monoclonal antibodies against hendra and nipah viruses
AssigneesThe Henry Jackson Foundation for the Advancement of Military Medicine, The United States of America as represented by the Secretary, Department of Health and Human Services; National Institutes of Health, Office of Technology Transfer
InventorsDimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
Life of this patent
Estimating the term…
Abstract
The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
Claims14
An antibody that selectively binds a Hendra or Nipah G glycoprotein epitope, wherein said antibody includes a variable light chain with the amino acid sequence of SEQ ID NO:313 and a heavy chain CDR3 region having the amino acid sequence of SEQ ID NO:
- 311.
Dependencies are inferred from the claim text.